Donor-specific B cells in Transplantation
移植中的供体特异性 B 细胞
基本信息
- 批准号:10473828
- 负责人:
- 金额:$ 53.02万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-09-22 至 2025-08-31
- 项目状态:未结题
- 来源:
- 关键词:AffinityAllogenicAntibodiesAntigensAvidityB cell repertoireB-LymphocytesBindingBiologicalBloodCellsCharacteristicsChronicClone CellsComplement ActivationDiagnosticDonor personEvolutionExhibitsFrequenciesGenesGlycocalyxGoalsGraft RejectionGraft SurvivalImmuneImmunoglobulin Somatic HypermutationImmunoglobulinsInterventionInvestigationKidney TransplantationLightMediatingMethodsMutateMutationOutcomePathogenicityPhenotypeProductionPropertyProspective StudiesRecombinantsRecoveryResearchRiskSerumSignal TransductionSomatic MutationSpecificityT-LymphocyteTestingTimeTissue GraftsTransplant RecipientsTransplantationantibody-mediated rejectioncytokinedonor-specific antibodygraft functionimmunoregulationindexinginterestisoimmunitylongitudinal analysisnext generation sequencingnovel strategiespersonalized therapeuticresponsesample fixationsingle cell sequencingtherapeutic developmenttranscriptome sequencing
项目摘要
Abstract
Kidney transplantation elicits powerful B cell responses that generate antibodies specific for the transplant
donor. B cell responses to allogeneic HLA (panel reactive antibodies, PRA) and to the transplant donor (donor-
specific antibodies, DSA) correlate with risk of rejection and graft loss and thus serve as diagnostic indices of
allo-immunity. B cell responses that generate DSA initiate the most vexing types of rejection (antibody-
mediated rejection, ABMR) and chronic ABMR and hence much interest exists in development of therapeutics
that specifically target B cells. Some B cell responses however may correlate with or even promote graft
survival (immune regulation, accommodation, operational tolerance). Although there has been extensive
investigation of the specificity and function of the blood DSA hardly anything is known about the properties of
donor-specific B cells. The research we propose will identify for the first time key characteristics of
donor-specific B cell responses in kidney transplant recipients to determine what properties associate
with and potentially contribute to stable graft function, as opposed to rejection. As a first objective,
donor-specific B cell responses will be studied by determining Heavy and Light chain Ig sequences of donor-
specific B cells by single cell sequencing and their phenotypic signature by RNA-seq . We will determine key
properties of Ig, such as clonal diversity, extent of somatic hypermutation or Ig independent properties such as
production of cytokines in recipients with stable function or rejection. As a second objective, donor-specific Ig
sequences obtained by NGS will be studied prospectively over periods > a year (up to two years). We will
determine whether clonotypes expand and diversify in anticipation of rejection as would be expected of T cell
dependent responses; and how donor-specific sequences change following rejection treatment. We will also
determine if in recipients with stable grafts, donor-specific B cells encode Igs with distinct properties. As a third
objective, we will conduct the first investigation of key properties (e.g. maximum binding, avidity, direct
activation of donor cells and antigen specificity, where possible, confirmed using graft tissues) of recombinant
monoclonal DSA on donor cells to determine whether these properties could explain differences in
pathogenicity. The research might reveal novel approaches to assessing risk and new targets for biological
intervention. The research might also inspire rational approaches to modifying B cell responses in transplant
recipients in a personalized manner with the goal of promoting protective responses and antagonizing
pathogenic ones.
抽象的
肾移植引发强大的 B 细胞反应,产生针对移植物的特异性抗体
捐助者。 B 细胞对同种异体 HLA(面板反应性抗体,PRA)和移植供体(供体)的反应
特异性抗体(DSA)与排斥和移植物丢失的风险相关,因此可以作为以下疾病的诊断指标:
同种异体免疫。产生 DSA 的 B 细胞反应会引发最令人烦恼的排斥类型(抗体-
介导的排斥反应(ABMR)和慢性 ABMR,因此对治疗方法的开发存在很大兴趣
专门针对 B 细胞。然而,一些 B 细胞反应可能与移植相关甚至促进移植
生存(免疫调节、调节、操作耐受性)。虽然已经有广泛
血液 DSA 的特异性和功能的研究 对血液 DSA 的特性几乎一无所知
供体特异性 B 细胞。我们提出的研究将首次确定
肾移植受者体内供体特异性 B 细胞反应,以确定相关特性
具有并可能有助于稳定的移植功能,而不是排斥。作为首要目标,
供体特异性 B 细胞反应将通过确定供体的重链和轻链 Ig 序列来研究
通过单细胞测序确定特定 B 细胞,并通过 RNA-seq 确定其表型特征。我们将确定关键
Ig 的特性,例如克隆多样性、体细胞超突变程度或 Ig 独立特性,例如
功能稳定或排斥反应的受者体内产生细胞因子。作为第二个目标,捐赠者特异性 Ig
通过 NGS 获得的序列将在一年以上(最多两年)的时间内进行前瞻性研究。我们将
确定克隆型是否会像 T 细胞预期的那样在预期排斥反应中扩展和多样化
相关反应;以及排斥治疗后供体特异性序列如何变化。我们也会
确定在具有稳定移植物的受体中,供体特异性 B 细胞是否编码具有不同特性的 Igs。作为第三个
目标,我们将首先对关键属性进行调查(例如最大结合力、亲合力、直接
供体细胞的激活和抗原特异性(在可能的情况下,使用移植组织进行确认)重组
对供体细胞进行单克隆 DSA 以确定这些特性是否可以解释
致病性。该研究可能揭示评估风险的新方法和生物治疗的新目标
干涉。该研究还可能激发修改移植中 B 细胞反应的合理方法
以个性化的方式向接收者提供信息,目的是促进保护性反应并对抗
致病的。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MARILIA Isabel CASCALHO其他文献
MARILIA Isabel CASCALHO的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MARILIA Isabel CASCALHO', 18)}}的其他基金
TNFRSF13B polymorphisms and immunity to transplantation
TNFRSF13B 多态性与移植免疫
- 批准号:
10734879 - 财政年份:2023
- 资助金额:
$ 53.02万 - 项目类别:
TNRSF13B polymorphisms and the control of innate B cell responses – a double edged sword
TNRSF13B 多态性和先天 B 细胞反应的控制——一把双刃剑
- 批准号:
10330588 - 财政年份:2021
- 资助金额:
$ 53.02万 - 项目类别:
TNRSF13B polymorphisms and the control of innate B cell responses – a double edged sword
TNRSF13B 多态性和先天 B 细胞反应的控制——一把双刃剑
- 批准号:
10192900 - 财政年份:2021
- 资助金额:
$ 53.02万 - 项目类别:
A novel rabbit model for easy monoclonal antibody production
一种易于单克隆抗体生产的新型兔模型
- 批准号:
10264143 - 财政年份:2020
- 资助金额:
$ 53.02万 - 项目类别:
B cell reaponses and cardiac transplantation in infancy
婴儿期 B 细胞反应和心脏移植
- 批准号:
7474546 - 财政年份:2007
- 资助金额:
$ 53.02万 - 项目类别:
B cell reaponses and cardiac transplantation in infancy
婴儿期 B 细胞反应和心脏移植
- 批准号:
7312641 - 财政年份:2006
- 资助金额:
$ 53.02万 - 项目类别:
相似国自然基金
抗骨髓瘤的新型同种异体嵌合抗原受体T(CAR T)细胞疗法研发
- 批准号:82270210
- 批准年份:2022
- 资助金额:68 万元
- 项目类别:面上项目
过表达MicroRNA-199a-3p的BMSCs来源的外泌体抑制小鼠DC功能诱导同种异体心脏移植免疫耐受的机制研究
- 批准号:82160081
- 批准年份:2021
- 资助金额:34 万元
- 项目类别:地区科学基金项目
胸腺上皮细胞在小鼠后肢同种异体复合组织移植中的免疫调节作用及相关机制研究
- 批准号:82102354
- 批准年份:2021
- 资助金额:30 万元
- 项目类别:青年科学基金项目
具有靶向识别和序贯治疗功能的纳米微球对血管化同种异体复合组织移植术后免疫抑制的研究
- 批准号:
- 批准年份:2020
- 资助金额:24 万元
- 项目类别:青年科学基金项目
基于T细胞亚群分化与TLR2/TRAF6信号通路探讨ESAT-6抑制同种异体移植排斥的分子免疫机制
- 批准号:82071800
- 批准年份:2020
- 资助金额:55 万元
- 项目类别:面上项目
相似海外基金
Engineering Protein Modulators of Notch Activation for T-cell immunotherapy
用于 T 细胞免疫治疗的 Notch 激活的工程蛋白质调节剂
- 批准号:
10612995 - 财政年份:2023
- 资助金额:
$ 53.02万 - 项目类别:
Molecular determinants of anti-RBC alloantibody evanescence
抗红细胞同种抗体消失的分子决定因素
- 批准号:
10687424 - 财政年份:2022
- 资助金额:
$ 53.02万 - 项目类别:
Fibrin-CAR-T cells therapies to enhance efficacy in glioblastoma treatments
纤维蛋白-CAR-T 细胞疗法可增强胶质母细胞瘤治疗的疗效
- 批准号:
10515887 - 财政年份:2022
- 资助金额:
$ 53.02万 - 项目类别:
Exploiting the VISTA Pathway to Prevent Acute GVHD and Control Steroid Refractory Disease
利用 VISTA 途径预防急性 GVHD 和控制类固醇难治性疾病
- 批准号:
10092348 - 财政年份:2021
- 资助金额:
$ 53.02万 - 项目类别:
Exploiting the VISTA Pathway to Prevent Acute GVHD and Control Steroid Refractory Disease
利用 VISTA 途径预防急性 GVHD 和控制类固醇难治性疾病
- 批准号:
10560605 - 财政年份:2021
- 资助金额:
$ 53.02万 - 项目类别: